HIV associated lymphoma: latest updates from 2023 ASH annual meeting.

IF 9.4 1区医学 Q1 HEMATOLOGY

Experimental Hematology & Oncology Pub Date : 2024-07-05 DOI:10.1186/s40164-024-00530-6

Chaoyu Wang, Qing Xiao, Xiaomei Zhang, Yao Liu

引用次数: 0

Abstract

The incidence, clinical characteristics, and prognostic factors of HIV-associated lymphoma remain poorly defined compared to HIV-negative lymphoma. Currently, there are no standard guidelines for treatment of these patients. We summarized several latest reports of HIV associated lymphoma from the 2023 ASH Annual Meeting (ASH2023).

查看原文本刊更多论文

艾滋病相关淋巴瘤：2023 年 ASH 年会的最新进展。

与 HIV 阴性淋巴瘤相比，HIV 相关淋巴瘤的发病率、临床特征和预后因素仍不十分明确。目前，还没有治疗这些患者的标准指南。我们总结了2023年ASH年会（ASH2023）上关于HIV相关淋巴瘤的几篇最新报道。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Experimental Hematology & Oncology Medicine-Oncology

CiteScore

12.60

自引率

7.30%

发文量

审稿时长

6 weeks

期刊介绍： Experimental Hematology & Oncology is an open access journal that encompasses all aspects of hematology and oncology with an emphasis on preclinical, basic, patient-oriented and translational research. The journal acts as an international platform for sharing laboratory findings in these areas and makes a deliberate effort to publish clinical trials with 'negative' results and basic science studies with provocative findings. Experimental Hematology & Oncology publishes original work, hypothesis, commentaries and timely reviews. With open access and rapid turnaround time from submission to publication, the journal strives to be a hub for disseminating new knowledge and discussing controversial topics for both basic scientists and busy clinicians in the closely related fields of hematology and oncology.